Jonah Rainey
Associate Vice President Eli Lilly & Co.
Dr. G. Jonah Rainey is Senior Director of Protein/Antibody Engineering at Eli Lilly & Company, where he leads discovery and engineering efforts spanning next‑generation bispecific antibodies and T‑cell engager platforms. He brings more than 15 years of experience advancing multispecific biologics across oncology, infectious disease, autoimmunity, and other therapeutic areas. Throughout his career, he has contributed to the research and early development of multiple candidates that progressed from preclinical stages into clinical trials and approved products. pegsummit.com
Before joining Eli Lilly, Dr. Rainey held scientific and leadership roles at MacroGenics, MedImmune/AstraZeneca, Oriole Biotech, Gritstone Oncology, MabVax Therapeutics, and AlivaMab Discovery Services, where he helped drive programs across antibody engineering, biologics discovery, and translational research. rocketreach.co
He holds a PhD in Biochemistry and Microbiology from Tufts University School of Medicine, followed by postdoctoral training at the University of Wisconsin and the Salk Institute. Dr. Rainey is an inventor on several patents describing novel bispecific platforms and has authored nearly 30 scientific publications.
Seminars
- Reflecting on the move away from first generation BiTE molecules to next-generation logic-gated and multi-specific T cell engagers
- Exploring advancements in preclinical and clinical modelling of TCEs to allow for improvements in efficacy whilst minimizing system toxicity
- Evaluating the potential for TCEs to serve as a scalable, off-the-shelf alternative to personalized CAR-T therapies
